{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-393116","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-09-16T20:25:25+00:00","discovered_at":"2026-09-16T20:26:02.242539+00:00","generated_at":"2026-09-16T20:26:11.260552+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Teva issues €1.5B and $3.2B senior notes; proceeds to redeem existing notes","bullets":["Issued €1.0B 4.250% notes due 2033 and €0.5B 4.625% notes due 2036.","Issued $1.0B 5.500% notes due 2034, $1.0B 5.750% notes due 2037, and $1.2B 5.250% notes due 2032.","Proceeds redeem all 6.750% 2028, 7.875% 2029, 7.375% 2029, and 8.125% 2031 notes; up to $450M of 2027 notes and €1.15B of 2030 notes.","Remaining proceeds for general corporate purposes; notes guaranteed by Teva on senior unsecured basis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-393116","json":"https://secwatch.observer/filing/0001193125-26-393116.json","markdown":"https://secwatch.observer/filing/0001193125-26-393116.md","text":"https://secwatch.observer/filing/0001193125-26-393116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/0001193125-26-393116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:26:11.260552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}